Regencell Bioscience Holdings Ltd (RGC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Regencell Bioscience Holdings Ltd (RGC) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：26.10

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Regencell Bioscience Holdings Ltd (RGC) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Regencell Bioscience Holdings Ltd (RGC) has a current Price-to-Book (P/B) ratio of 2089.95. Compared to its 3-year average P/B ratio of 380.06, the current P/B ratio is approximately 449.90% higher. Relative to its 5-year average P/B ratio of 239.72, the current P/B ratio is about 771.84% higher. Regencell Bioscience Holdings Ltd (RGC) has a Forward Free Cash Flow (FCF) yield of approximately -0.03%. Compared to its 3-year average FCF yield of -1.30%, the current FCF yield is approximately -97.53% lower. Relative to its 5-year average FCF yield of -0.92%, the current FCF yield is about -96.49% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RGC competitors is 7.48, providing a benchmark for relative valuation. Regencell Bioscience Holdings Ltd Corp (RGC.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RGC increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RGC in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RGC currently overvalued or undervalued?

What is Regencell Bioscience Holdings Ltd (RGC) fair value?

RGC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Regencell Bioscience Holdings Ltd (RGC) is between to according to relative valuation method.

How does RGC's valuation metrics compare to the industry average?

The average P/S ratio for RGC's competitors is 7.48, providing a benchmark for relative valuation. Regencell Bioscience Holdings Ltd Corp (RGC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Regencell Bioscience Holdings Ltd (RGC) as of Mar 03 2026?

As of Mar 03 2026, Regencell Bioscience Holdings Ltd (RGC) has a P/B ratio of 2089.95. This indicates that the market values RGC at 2089.95 times its book value.

What is the current FCF Yield for Regencell Bioscience Holdings Ltd (RGC) as of Mar 03 2026?

As of Mar 03 2026, Regencell Bioscience Holdings Ltd (RGC) has a FCF Yield of -0.03%. This means that for every dollar of Regencell Bioscience Holdings Ltd's market capitalization, the company generates -0.03 cents in free cash flow.

What is the current Forward P/E ratio for Regencell Bioscience Holdings Ltd (RGC) as of Mar 03 2026?

As of Mar 03 2026, Regencell Bioscience Holdings Ltd (RGC) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Regencell Bioscience Holdings Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Regencell Bioscience Holdings Ltd (RGC) as of Mar 03 2026?

As of Mar 03 2026, Regencell Bioscience Holdings Ltd (RGC) has a Forward P/S ratio of 0.00. This means the market is valuing RGC at $0.00 for every dollar of expected revenue over the next 12 months.

RGC Valuation